In a strategic move to cement its leadership in the booming cardiometabolic therapeutics market, Danish pharmaceutical titan Novo Nordisk has…
Read More
Novo Nordisk Secures $1.33bn Nanexa Licensing Deal to Accelerate Long-Acting Cardiometabolic Therapies
The global pharmaceutical landscape is undergoing a profound structural evolution, driven by surging demand for treatments addressing obesity, type 2…
Read More
Novo Nordisk’s ziltivekimab misses Phase 3 primary endpoint
In a significant setback for Novo Nordisk’s ambitions to diversify its cardiovascular pipeline, the company announced that its investigational human…
Read More
Novo Unveils Post-Wegovy Growth Roadmap as Shares Slide Despite Ambitious 2030 Targets
The pharmaceutical landscape is undergoing a profound transformation, and Danish drugmaking giant Novo is aggressively positioning itself for a future…
Read More
Novo Secures $1.4bn Partnership With Orbis Medicines to Bolster Cardiometabolic Pipeline Through AI-Driven Macrocycle Therapeutics
In a strategic move to fortify its cardiovascular and metabolic disease pipeline following a sequence of high-profile clinical and commercial…
Read More
Novo Partners with Anthropic to Harness Claude AI in Ambitious R&D Overhaul
Pharmaceutical giant Novo has announced a strategic partnership with artificial intelligence pioneer Anthropic, leveraging the tech company’s advanced AI assistant,…
Read More
Novo Nordisk Drops Nordisk in Major Rebrand to Modernise Identity Amid Fierce Competition in Obesity and Diabetes Markets
The pharmaceutical landscape is undergoing a quiet yet profound visual and strategic evolution, and one of its most prominent titans…
Read More
Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Advertising of Obesity Drugs
The escalating rivalry between pharmaceutical giants Novo Nordisk and Eli Lilly has reached a new legal frontier, with Novo Nordisk…
Read More
Novo Nordisk Secures European Approval for Oral Wegovy, Bolstering First-Mover Advantage in Obesity Pill Market
Novo Nordisk has solidified its pioneering position in the burgeoning market for oral obesity medications with the European Commission’s marketing…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company has announced groundbreaking Phase 3 results for its investigational triple agonist, retatrutide, demonstrating significant efficacy in…
Read MoreYOU MAY HAVE MISSED
